Purpose of this Study
We are doing this study to find out if an experimental drug called MEM-288 (the study drug) is a safe and effective treatment for your cancer.
Who Can Participate?
Eligibility
Adults diagnosed with the following cancers that have spread:
- Non-small cell lung cancer (NSCLC)
- Cutaneous squamous-cell carcinoma (cSCC)
- Merkel cell carcinoma
- Melanoma
- Triple negative breast cancer (TNBC)
- Pancreatic cancer
- Head and neck cancer
- Non-small cell lung cancer (NSCLC)
- Cutaneous squamous-cell carcinoma (cSCC)
- Merkel cell carcinoma
- Melanoma
- Triple negative breast cancer (TNBC)
- Pancreatic cancer
- Head and neck cancer
What is Involved?
If you choose to join this study, you will:
- Take the study drug (MEM-288)
- Provide tumor tissue
- Have physical exams, blood draws, and give urine samples
- Have imaging scans (CT and MRI)
- Have heart tests (ECG)
- Take the study drug (MEM-288)
- Provide tumor tissue
- Have physical exams, blood draws, and give urine samples
- Have imaging scans (CT and MRI)
- Have heart tests (ECG)
Study Details
Full Title
Phase I Study of MEM-288 Oncolytic Virus Alone and in Combination with Nivolumab in Solid Tumors including Non-Small Cell Lung Cancer (NSCLC)
Principal Investigator
Neal
Ready
Protocol Number
PRO00109517
NCT ID
NCT05076760
Phase
I
Enrollment Status
OPEN TO ACCRUAL